07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

NDV-3A: Phase IIa data

Data from the Phase IIa portion of a double-blind, placebo-controlled, U.S. Phase Ib/IIa trial in 188 patients with >=3 episodes of vulvovaginal candidiasis in the past 12 months showed that single doses of 300 ug...
00:34 , Oct 4, 2013 |  BC Extra  |  Financial News

NovaDigm closes $14 million in tranched series B

NovaDigm Therapeutics Inc. (Grand Forks, N.D.) secured $14 million in a tranched series B round from new investor Rusnano, the state-funded $10 billion Russian fund, and existing investor Domain Associates. NovaDigm raised $7 million in...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

NDV-3A: Phase Ib/IIa started

NovaDigm began a double-blind, placebo-controlled, U.S. Phase Ib/IIa trial to evaluate single intramuscular vaccinations of NDV-3A in about 189 patients with recurrent vulvovaginal candidiasis. The Phase Ib portion is comparing vaccines with histidine-tagged (NDV-3A) and...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

NDV-3: Phase I data

A double-blind, placebo-controlled Phase I trial in 160 healthy volunteers showed that single doses of intramuscular 300 µg NDV-3 with or without alum adjuvant and single doses of intradermal 30 µg NDV-3 without alum adjuvant...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

NDV-3: Phase I data

A double-blind, placebo-controlled Phase I trial in 40 healthy volunteers showed that single doses of 30 and 300 µg NDV-3 resulted in 100% seroconversion of both serum IgG and IgA1 antibodies by day 14, with...